Post-exposure prophylaxis: time-critical initiation, risk-based triage, standard 3-drug regimen, 28-day adherence, and follow-up serology
Post-exposure prophylaxis works by suppressing HIV replication before the virus can establish a permanent, irreversible infection in the earliest founder cells and regional lymph nodes. That biological race against time is the reason PEP guidelines are built around urgency: initiation is recommended as soon as possible after exposure, ideally within a few hours, and is generally not offered beyond 72 hours because the window of opportunity to prevent systemic infection has likely closed.
After mucosal or percutaneous exposure, HIV does not immediately achieve systemic, irreversible infection. In the earliest hours, the virus first infects a small population of local dendritic cells and CD4+ T cells at or near the site of entry (skin, mucosa, or directly into the bloodstream for percutaneous exposures). Over roughly 24–72 hours, infected cells migrate to draining lymph nodes, where explosive local viral replication seeds the wider lymphoid system. Once this dissemination occurs, the infection is essentially unstoppable by antiretroviral drugs alone — the "founder" viral reservoir is established.
PEP works by suppressing viral replication during this local, pre-systemic phase, giving the innate and adaptive immune system time to clear the small initial inoculum before it can propagate. This is why PEP is fundamentally different from treatment of established HIV infection: it is a race to prevent seeding, not a treatment for an ongoing infection.
Non-human primate (SIV/SHIV macaque) challenge-and-treat studies are the main experimental evidence for the time-sensitivity of PEP, since randomized human trials of delayed initiation would be unethical. These studies consistently show that protection is high when antiretrovirals are started within 24–36 hours, declines substantially by 48–72 hours, and is largely lost beyond 72 hours.
The 72-hour cutoff is not a sharp biological boundary — it is a conservative, evidence-informed guideline threshold. Protection is not binary at the 72-hour mark; efficacy declines progressively with every hour of delay, which is why "as soon as possible" is emphasized far more than "before 72 hours" in current clinical guidance.
Because delay directly erodes efficacy, PEP care pathways are designed to minimize any friction between exposure and first dose:
• Immediate first aid: wash the exposed area with soap and water (percutaneous) or flush mucous membranes with water/saline; do not use caustic agents, bleach, or attempt to "squeeze out" blood, as these do not reduce risk and may cause tissue damage. • Same-day evaluation: emergency departments, occupational health services, sexual health clinics, and many pharmacies are equipped to assess exposure and, where indicated, dispense a starter pack (typically 3–7 days) of PEP on the spot, before full risk assessment or source-patient testing is complete. • "Start now, decide later" principle: when there is uncertainty about source HIV status or exposure severity, most protocols favor starting PEP immediately and stopping later if risk assessment or source testing rules out significant exposure, rather than delaying to gather more information. • Beyond 72 hours: PEP is generally not recommended because the marginal benefit is believed to be low and does not clearly outweigh drug toxicity, cost, and adherence burden — though clinicians may still individualize decisions for exceptionally high-risk exposures presenting slightly outside the window.
Not all exposures carry the same risk of HIV transmission. Per-act transmission probabilities vary by more than 30-fold depending on the route and nature of contact. Rapid, structured risk categorization at the point of care determines whether PEP is indicated at all, how urgently it should begin, and helps counsel the exposed person on the (often overestimated) magnitude of their actual risk.
Healthcare and laboratory workers remain a core population for PEP protocols. Risk assessment for occupational exposure considers:
• Type of injury: hollow-bore needle vs. solid suture needle; depth of penetration; visible blood on the device — all increase transmission risk. • Source patient status: known HIV-positive with detectable viral load carries the highest risk; a source with undetectable viral load on stable antiretroviral therapy carries effectively negligible transmission risk (Undetectable = Untransmittable principles extend conceptually to occupational risk, though PEP is still typically offered when source status is unconfirmed). • Body fluid type: blood, visibly bloody fluid, semen, vaginal secretions, and several other fluids are considered potentially infectious; saliva, urine, tears, and sweat are not considered infectious unless visibly blood-contaminated. • Average risk estimates: percutaneous (needlestick) exposure to known HIV-positive blood carries an average transmission risk of about 0.3% per exposure; mucous membrane exposure (eye, nose, mouth splash) carries roughly 0.09%; intact skin contact carries effectively no risk.
Sexual exposure risk varies more widely than occupational risk and depends on the specific act, position, and presence of risk-modifying factors:
• Receptive anal intercourse: highest per-act risk among common sexual exposures, commonly cited around 1–1.4%, reflecting the thinner, more easily traumatized rectal mucosa and its dense population of susceptible immune cells. • Insertive anal intercourse: substantially lower, roughly 0.1%, though still meaningful. • Receptive vaginal intercourse: roughly 0.08%, with wide reported ranges depending on study population and cofactors. • Insertive vaginal intercourse: lower still, roughly 0.04%. • Receptive oral sex: very low but not zero risk, generally considered negligible in most guidelines unless other cofactors are present.
Risk-amplifying cofactors apply across all exposure types and should raise urgency and regimen consideration even for acts with lower baseline risk: a source with high or unknown viral load (e.g., acute/early HIV infection, which carries disproportionately high transmissibility), presence of genital ulcer disease or other sexually transmitted infections, traumatic or condomless contact, and multiple exposures.
Because per-act risk estimates carry wide confidence intervals and depend heavily on unmeasured cofactors, most current guidelines de-emphasize precise risk-based triage between different sexual exposure types and instead recommend offering PEP whenever a plausible, non-negligible exposure has occurred within the eligible time window — shifting the harder judgment to viral load status of the source rather than act type alone.
Modern PEP protocols increasingly avoid complex risk-scoring tables in favor of a simplified binary decision: is there a plausible route of transmission, and did it occur within the eligible time window? If yes to both, PEP is generally offered regardless of the precise numerical risk, because the harm of a missed HIV infection vastly outweighs the harm of an unnecessary 28-day antiretroviral course. Risk categorization is still used, however, to counsel patients realistically about their odds, to prioritize urgent same-day evaluation for higher-risk categories, and to guide source-patient testing efforts.
Older PEP guidance stratified regimens by perceived risk: a 2-drug NRTI-only regimen for "lower-risk" exposures and a 3-drug regimen reserved for "higher-risk" ones. Contemporary guidelines have largely abandoned this distinction. Because modern integrase-inhibitor-based regimens are highly tolerable, rapidly potent, and forgiving of imperfect adherence, most guidance now recommends a 3-drug regimen for essentially all PEP cases, regardless of the exposure risk category identified in Stage 2.
The shift to universal 3-drug PEP reflects several converging developments in antiretroviral pharmacology:
• Integrase strand transfer inhibitors (INSTIs) such as dolutegravir and raltegravir block HIV replication at a different step (viral DNA integration into the host genome) than the reverse-transcriptase-inhibiting NRTI backbone, providing an additional, mechanistically distinct barrier to establishing infection. • INSTIs achieve rapid viral suppression, have a high genetic barrier to resistance (particularly dolutegravir), and are dramatically better tolerated than the protease-inhibitor-based 3-drug regimens used in earlier PEP eras (which caused significant gastrointestinal side effects and were a major driver of early discontinuation). • With a well-tolerated 3-drug option available, the rationale for reserving 3 drugs only for "high-risk" exposures — namely avoiding unnecessary toxicity in "low-risk" cases — largely disappears, while the theoretical benefit of an added drug class remains for every case where transmission risk is nonzero. • Simplifying to a single universal regimen also reduces clinical decision complexity in the exact moment (urgent, time-pressured, often after-hours) when speed of prescribing matters most — reinforcing the Stage 1 imperative to minimize delay.
Typical modern first-line PEP: tenofovir disoproxil fumarate + emtricitabine (often as a single fixed-dose combination tablet, one per day) plus dolutegravir (one tablet per day) or raltegravir (one or two tablets daily depending on formulation) — a once- or twice-daily regimen designed to maximize adherence over the full 28 days.
While the NRTI backbone plus INSTI approach is now standard, individual regimen choice still accounts for:
• Renal function: tenofovir disoproxil fumarate requires dose adjustment or an alternative (e.g., zidovudine-based backbone, or tenofovir alafenamide where available) in significant renal impairment. • Drug-drug interactions and pregnancy status: dolutegravir has historically carried cautious counseling around use very early in pregnancy due to an initially reported (and since substantially reassessed) neural tube defect signal; raltegravir is often preferred when this concern is prioritized, though current guidance increasingly supports dolutegravir use in pregnancy given updated safety data. • Source virus resistance data, when available: if the source person's virus is known to carry specific resistance mutations, the regimen can be adjusted accordingly in consultation with an HIV specialist — though this should never delay first-dose administration. • Formulation and pill burden: once-daily, low pill-count regimens are preferred specifically because they measurably improve the Stage 4 adherence outcomes that determine whether the regimen actually works.
Starting PEP promptly solves only half the problem. The full protective effect depends on maintaining adequate antiretroviral drug levels for the entire 28-day course, allowing the immune system time to fully clear any initial infected cells. Historical PEP cohorts consistently show that a meaningful fraction of patients do not complete the course — most commonly due to side effects, low perceived risk after initial counseling, or difficulty accessing follow-up medication — making adherence support as clinically important as the drug regimen itself.
The 28-day duration is not an arbitrary round number — it reflects estimates of how long it takes for the immune system to definitively clear a small, localized initial viral inoculum without the assistance of ongoing drug-mediated suppression, based on modeling from animal challenge studies and clinical experience. Stopping early, even after 2–3 weeks, can allow residual infected cells that were being suppressed — but not yet eliminated — to resume replication once drug levels fall, effectively negating much of the protective benefit built up during the days the person did take medication.
Unlike antibiotics, where "finishing the course" debates involve resistance concerns for an established infection, PEP's full-course requirement is about preventing an infection from ever becoming established in the first place — every day of the 28 matters toward that cumulative goal.
Adherence research from the PEP era identifies recurring barriers:
• Medication side effects: older protease-inhibitor-based regimens caused substantial gastrointestinal side effects that drove early discontinuation; modern INSTI-based regimens (Stage 3) are markedly better tolerated, directly improving completion rates. • Access and cost: running out of the initial starter pack (often only 3–7 days) before a follow-up prescription is filled is a well-documented completion gap — many programs now dispense the full 28-day supply at the first visit when feasible. • Psychological factors: anxiety around the exposure event itself, stigma, and the practical burden of a month-long daily regimen for what may ultimately have been a low-probability exposure can all reduce motivation to continue once initial fear subsides. • Follow-up visit attendance: some protocols schedule a check-in around day 3–7 to confirm tolerability, answer questions, and reinforce the importance of completing the remaining course — this contact point is strongly associated with improved completion.
Adherence counseling, side-effect management (e.g., anti-nausea medication as needed), simplified once-daily dosing, and dispensing a full 28-day supply up front (rather than a short starter pack requiring a refill) are the interventions most consistently associated with higher PEP course completion rates.
PEP is not considered complete when the last pill is taken. A structured follow-up testing schedule confirms that seroconversion did not occur, provides an opportunity to reassess ongoing risk and consider transition to pre-exposure prophylaxis (PrEP), and captures the (rare) cases of PEP failure early enough to begin standard HIV treatment without delay.
Before or at the moment PEP is started, a baseline HIV test is performed — not to delay treatment (first-dose administration should never wait for results), but to document that the exposed person was not already HIV-positive from a prior, unrelated exposure. If baseline testing later returns positive, it indicates pre-existing infection rather than a new one from the exposure being managed, which changes clinical management from prophylaxis to full antiretroviral treatment and resistance testing.
Baseline testing typically uses a 4th-generation antigen/antibody combination immunoassay, which can detect the p24 antigen during acute infection days to weeks before antibody-only tests would turn positive — important because a person could theoretically present for PEP shortly after an earlier, separate exposure that is already in its acute window.
Follow-up testing intervals are timed to the HIV diagnostic window period — the time between infection and a test reliably detecting it:
• 6 weeks post-exposure: many current protocols consider a negative 4th-generation antigen/antibody test at this point highly reassuring, given the improved early sensitivity of modern assays compared to older antibody-only tests. • 3 months post-exposure: widely used as the definitive endpoint for ruling out infection with high confidence across essentially all available testing technologies, including in settings using older or antibody-only assays. • 6 months post-exposure: reserved in some guidelines for specific situations — such as concurrent hepatitis C exposure (which can theoretically delay HIV seroconversion in rare cases) or when only third-generation antibody-only testing was available — rather than as a routine requirement for all patients.
At each follow-up visit, clinicians also reassess ongoing HIV risk. A person who required PEP due to an ongoing pattern of exposure (rather than a single isolated event) is an important candidate for transition to daily or on-demand pre-exposure prophylaxis (PrEP) once the PEP course is complete, to prevent needing repeated PEP courses in the future.
A confirmed negative test at the 3-month mark, in a person who has had no interim exposures, is generally considered sufficient to conclude that PEP was successful and no further HIV testing related to that exposure is required — though clinicians tailor this based on assay generation and individual risk factors.